Boston, MA5 Active Studies

Stomach Cancer Clinical Trials in Boston, MA

Find 5 actively recruiting stomach cancer clinical trials in Boston, MA. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
1,997
Enrolling

Recruiting Stomach Cancer Studies in Boston

RecruitingBoston, MANCT06731478

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus stan...

726 participants
Daiichi Sankyo
View Study Details
RecruitingBoston, MANCT06901531

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with che...

500 participants
Astellas Pharma Global Development, Inc.
View Study Details
RecruitingBoston, MANCT04379596

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemoth...

413 participants
AstraZeneca
View Study Details
RecruitingBoston, MANCT05482893

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prelimi...

258 participants
Phanes Therapeutics
View Study Details
RecruitingBoston, MANCT04725994

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer

This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric ca...

100 participants
Idience Co., Ltd.
View Study Details

About Stomach Cancer Clinical Trials in Boston

Stomach (gastric) cancer develops in the lining of the stomach and is more common in certain regions of the world. Risk factors include H. pylori infection, smoking, and diet. Treatment includes surgery, chemotherapy, radiation, and immunotherapy.

There are currently 5 stomach cancer clinical trials recruiting participants in Boston, MA. These studies are seeking a combined 1,997 participants. Research is being sponsored by Daiichi Sankyo, Astellas Pharma Global Development, Inc., AstraZeneca and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Stomach Cancer Clinical Trials in Boston — FAQ

Are there stomach cancer clinical trials in Boston?

Yes, there are 5 stomach cancer clinical trials currently recruiting in Boston, MA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What stomach cancer treatments are being tested?

The 5 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for stomach cancer.

Data updated March 2, 2026 from ClinicalTrials.gov